Amarantus Bioscience Holdings Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Amarantus Bioscience Holdings Inc Reports Positive Results On MANF Neuroprotective Properties Demonstrated In Preclinical Study In China
Amarantus Bioscience Holdings Inc announced positive neuroprotective properties for the Company`s MANF therapeutic were reported in a preclinical research study conducted by the Department of Orthopaedics at Qilu Hospital of Shandong University, in Jinan, China. Specifically, a published abstract of the study concluded, These findings demonstrate that MANF shows the potential to alleviate cell damage and inflammation in rat primary astrocytes by suppressing ER (endoplasmic reticulum) stress, indicating that MANF plays an important role in astrocyte inflammation and functioning and may suggest a promising strategy for neuroprotection in the central nervous system. The findings from the study at Shandong University are consistent with the results obtained in own research with MANF on rat models for Parkinson`s disease, which were reported in March 2013. The independent research is contributing to the further understanding of MANF. The protective activity demonstrated by this independent work clearly suggests MANF may have utility in the treatment of conditions such as stroke, post-stroke recovery, Traumatic Brain Injury and concussion, as well as having relevance to the use of MANF in Parkinson`s disease. The Company will continue to conduct additional experiments with MANF in support of a planned Investigational New Drug (IND) application to the FDA.
Latest Developments for Amarantus Bioscience Holdings Inc
- Amarantus BioScience Holdings Inc closes warrant solicitation and enters into $20 mln purchase agreement with Lincoln Park Capital Fund, LLC
- Amarantus Bioscience Holdings Inc announcs positive clinical data for Eltoprazine in Phase 2a clinical study Adult Attention Deficit Hyperactivity Disorder
- Amarantus Bioscience Holdings Inc Announces Positive Analytical Performance Data for LymPro Test For Alzheimer's Disease
- Amarantus Bioscience Holdings Inc Announces Positive Orphan Data For MANF In Retinitis Pigmentosa
- Share this
- Digg this